Logo

ELVN

Enliven Therapeutics, Inc.

ELVN

Enliven Therapeutics, Inc. • NASDAQ
$21.60 ▼ -0.51% (-0.11)
Market Cap $1.28 B
52w High $25.96
52w Low $13.30
Dividend Yield 0%
P/E -11.93
Volume 189.26K
Outstanding Shares 59.35M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $25.096M ▼ $-20.148M ▲ 0% $-0.32 ▲ $-20.086M ▲
Q2-2025 $0 $28.584M ▼ $-25.335M ▲ 0% $-0.49 ▲ $-28.503M ▲
Q1-2025 $0 $31.693M ▲ $-28.544M ▼ 0% $-0.57 ▼ $-31.619M ▼
Q4-2024 $0 $26.896M ▼ $-23.18M ▼ 0% $-0.46 ▲ $-26.816M ▲
Q3-2024 $0 $27.068M $-23.156M 0% $-0.48 $-26.988M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $477.565M ▼ $490.875M ▼ $14.753M ▼ $476.122M ▼
Q2-2025 $490.503M ▲ $503.887M ▲ $15.415M ▲ $488.472M ▲
Q1-2025 $289.555M ▼ $302.57M ▼ $14.274M ▼ $288.296M ▼
Q4-2024 $313.44M ▲ $325.76M ▲ $15.915M ▼ $309.845M ▲
Q3-2024 $291.834M $305.43M $17.027M $288.403M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-20.148M ▲ $-13.279M ▲ $-4.058M ▲ $-368K ▼ $-17.705M ▼ $-13.278M ▲
Q2-2025 $-25.335M ▲ $-17.057M ▲ $-183.589M ▼ $218.378M ▲ $17.732M ▲ $-17.196M ▲
Q1-2025 $-28.544M ▼ $-24.127M ▼ $1.427M ▲ $234K ▼ $-22.466M ▼ $-24.147M ▼
Q4-2024 $-23.18M ▼ $-17.203M ▼ $727K ▼ $39.972M ▲ $23.496M ▲ $-17.203M ▼
Q3-2024 $-23.156M $-12.193M $14.826M $1.117M $3.75M $-12.215M

Five-Year Company Overview

Income Statement

Income Statement Enliven is still in the classic early‑stage biotech phase: it has no product revenue yet and runs entirely on research and development spending. Losses have been steady and rising over time as the company has scaled its clinical work, but they remain modest relative to many peers. The pattern is typical for a clinical‑stage biotech: expenses are largely research‑driven, and profitability will depend entirely on eventually bringing a drug to market or partnering it. Until then, investors should expect continued operating and net losses.

Balance Sheet

Balance Sheet The balance sheet looks clean and relatively conservative. Assets and cash have grown over the past few years, reflecting successful fund‑raising and a deliberate effort to build a cash cushion for trials. There is essentially no financial debt, which reduces financing risk and interest burden. Equity moved from negative to clearly positive, signaling that past balance‑sheet stress has been addressed through capital raises. The main risk is less about leverage and more about how long the current cash can support ongoing development.

Cash Flow

Cash Flow Cash flow is negative as the company funds research and clinical trials, with outflows primarily from operations and virtually no heavy investment in physical assets. This means cash burn is tied mostly to people, labs, and trials, not large fixed infrastructure. The reported runway into the second half of the decade suggests management has raised enough capital to get through several key clinical milestones, but that runway will naturally shorten if trial scope expands or timelines slip. Future financing needs remain likely if the company pushes toward commercialization on its own.

Competitive Edge

Competitive Edge Enliven is highly focused rather than broadly diversified. Its main strength is a narrow but deep expertise in precision oncology, particularly in kinase inhibitors aimed at patients who have exhausted existing options. The lead program, targeting resistant forms of chronic myeloid leukemia, goes after a defined niche where unmet medical need is still meaningful despite existing therapies. The field is crowded and dominated by large pharma players, so success depends on clearly better safety, efficacy, or resistance profiles. The company’s concentration in a single flagship asset increases upside if data are strong but also raises single‑asset risk.

Innovation and R&D

Innovation and R&D Innovation is the core of the story. Enliven is using structure‑based drug design and digital modeling to build highly selective kinase inhibitors, aiming to reduce side effects and overcome resistance. The lead candidate, ELVN‑001, is designed to work in heavily pre‑treated leukemia patients who no longer benefit from current drugs, with early data suggesting promising activity and tolerability. Management has deliberately streamlined the pipeline by de‑prioritizing a second program to channel resources into this lead asset, which can sharpen execution but reduces diversification. The underlying platform suggests the potential to generate additional drugs over time, though these are not yet central to the near‑term outlook.

Summary

Overall, Enliven is a focused, early‑stage oncology company with a clean balance sheet, predictable cash burn, and no current revenue. The investment thesis revolves almost entirely around the success of one lead drug candidate in a resistant leukemia setting. Financially, the lack of debt and solid cash runway are positives, but ongoing losses and eventual need for additional capital are typical sector risks. Scientifically, a strong specialization in precision kinase inhibitors and a clear plan for the lead asset provide a coherent story, but concentration risk is high and outcomes depend heavily on future clinical and regulatory results that are inherently uncertain.

NEWS

November 12, 2025 · 4:05 PM UTC

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

Read more